The inclusion criteria were: Population: Patients diagnosed with diabetic vitreous hemorrhage; Intervention: Anti-VEGF injections combined with vitrectomy; Comparison: Vitrectomy alone; Outcomes: At least one of the following: BCVA (at 1, 3, or 6 months) or recurrence of vitreous hemorrhage; Study design: Randomized controlled trials and non-randomized observational studies. This evidence concerns the gene VEGFA and vitreous hemorrhage.